Regulatory Ionis nets Zanvastro US approval in first for Alexander disease Pharmaceutical TechnologyIonis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease "in the coming weeks".Rare DiseaseRead full story pharminent September 4, 2026 (Last updated: September 7, 2026) Pharmaceutical Technology Ionis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease “in the coming weeks”. Rare Disease Read full story Post navigation Previous: Ivonescimab Beats Keytruda on Survival in China-Only Trial as Its Global Study StumblesNext: AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026